The global parkinson’s disease therapeutics market size was USD 6.19 billion in 2023, calculated at USD 6.59 billion in 2024 and is projected to surpass around USD 13.34 billion by 2034, expanding at a CAGR of 7.3% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Parkinson’s Disease Therapeutics Market
5.1. COVID-19 Landscape: Parkinson’s Disease Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Parkinson’s Disease Therapeutics Market, By Drug Class
8.1. Parkinson’s Disease Therapeutics Market, by Drug Class, 2024-2034
8.1.1 Levodopa/Carbidopa
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Dopamine Agonists
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Adenosine A2A Antagonist
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. COMT Inhibitors
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. MAO-B Inhibitors
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Glutamate Antagonist
8.1.6.1. Market Revenue and Forecast (2021-2034)
8.1.7. Others
8.1.7.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Parkinson’s Disease Therapeutics Market, By Route of Administration
9.1. Parkinson’s Disease Therapeutics Market, by Route of Administration, 2024-2034
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Transdermal
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Parkinson’s Disease Therapeutics Market, By Patient
10.1. Parkinson’s Disease Therapeutics Market, by Patient, 2024-2034
10.1.1. Adult
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Pediatric
10.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Parkinson’s Disease Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.1.3. Market Revenue and Forecast, by Patient (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Patient (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Patient (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.3. Market Revenue and Forecast, by Patient (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Patient (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Patient (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Patient (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Patient (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.3. Market Revenue and Forecast, by Patient (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Patient (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Patient (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Patient (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Patient (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.3. Market Revenue and Forecast, by Patient (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Patient (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Patient (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Patient (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Patient (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5.3. Market Revenue and Forecast, by Patient (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Patient (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Route of Administration (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Patient (2021-2034)
Chapter 12. Company Profiles
12.1. Cerevel Therapeutics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Hallamshire Physiotherapy Ltd
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Olatec Therapeutics
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Biotech Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Teva Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck & Co., Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. GlaxoSmithKline plc. (GSK)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AbbVie, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Acorda Therapeutics, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample